BiotechTube

Mesenchymal stem cell

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Acute Respiratory Syndrome Coronavirus 2

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2

Trial Timeline

Aug 21, 2020 → Feb 2, 2021

NCT ID
NCT04522986

About Mesenchymal stem cell

Mesenchymal stem cell is a phase 1 stage product being developed by Rohto Pharmaceutical for Severe Acute Respiratory Syndrome Coronavirus 2. The current trial status is completed. This product is registered under clinical trial identifier NCT04522986. Target conditions include Severe Acute Respiratory Syndrome Coronavirus 2.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT04522986Phase 1Completed
NCT03472742Pre-clinicalCompleted
NCT03254758Phase 1/2Completed

Competing Products

20 competing products in Severe Acute Respiratory Syndrome Coronavirus 2

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Rohto Pharmaceutical

Mesenchymal stem cell + PlaceboPhase 2
52
Mesenchymal stem cell + PlaceboPhase 2
52
Mesenchymal stem cellPhase 1/2
41
UDI-001Phase 1/2
41
infusion of ADR-001 (Mesenchymal stem cell)Phase 1
33